Cardiovascular Prevention and Rehabilitation — Viva Defence

Opening statement (SASPOP, delivered aloud)

"Mr Halloran is a 62-year-old man four months into recovery from an NSTEMI treated with a drug-eluting stent to the LAD. His main problems are: established secondary-prevention pharmacotherapy now partly self-ceased, with statin-associated muscle symptoms that need structured assessment; ongoing smoking, the single largest modifiable driver of his next event; non-attendance at cardiac rehabilitation, which forfeits a mortality-reducing intervention; and an information problem — he is making decisions from internet material rather than from a conversation with us. I would like to restore the full secondary prevention bundle using a validated statin protocol, engage him with rehabilitation and smoking cessation, and rebuild his trust in the plan." [1] [5]

Structured problem list

1. Established coronary disease post-NSTEMI with stent — mandates dual antiplatelet therapy for the guideline period, high-intensity statin, beta-blocker and ACE inhibitor; every element he stops raises his recurrent-event risk [6].
2. Statin-associated muscle symptoms, self-ceased 3 weeks ago — symmetrical thigh ache on atorvastatin 80 mg; no CK checked, no dechallenge-rechallenge, and a nocebo amplifier from internet reading [2].
3. Active smoking — 15 cigarettes daily after an NSTEMI is the highest-yield target in his entire risk profile; cessation support with pharmacotherapy, not advice alone [1].
4. Cardiac rehabilitation non-attendance — he is missing an intervention with a ~26% cardiovascular mortality reduction; I need to know why (work, transport, beliefs) and re-offer a format he can attend [5].
5. Adherence and health literacy — the unifying problem: his decisions are rational given what he has read, so the fix is information and partnership, not instruction.

Integrated management plan

• Quantify the statin problem properly. Characterise the ache, check CK, TSH, vitamin D, renal function and drug interactions. If CK is normal or modestly elevated and he is systemically well, explain the plan: a supervised dechallenge, then rechallenge at atorvastatin 40 mg or rosuvastatin 10–20 mg, titrating to the maximally tolerated dose [2].
• Share the SAMSON evidence in his language. "In a trial, people who had quit statins took statin, dummy tablets and nothing in random order — their muscle symptoms on the dummy tablet were the same as on the statin. Half got back on a statin once they saw that." Showing him his own pattern after rechallenge is more persuasive than any reassurance [2].
• Have the fallback ready. If two or three structured attempts fail, build LDL lowering on ezetimibe 10 mg (IMPROVE-IT outcomes evidence post-ACS), consider alternate-day rosuvastatin, and bempedoic acid 180 mg daily — which has outcomes evidence in exactly the statin-intolerant population (CLEAR Outcomes). For recurrent events with LDL still above target despite maximally tolerated therapy, a PCSK9 antibody is defensible on ODYSSEY OUTCOMES [3] [4] [7].
• Smoking cessation as treatment, not advice. Set a quit date, offer varenicline or combination nicotine replacement, link to quitline, and tie it to what he values — driving licence, grandchildren, work [1].
• Rehabilitation, second attempt. Ask why he did not attend; offer home-based or telehealth cardiac rehabilitation if work is the barrier, and confirm enrolment at the next visit rather than accepting a discharged referral [5].
• Targets and surveillance. LDL target below 1.4 mmol/L with at least a 50% fall from baseline, rechecked 6–8 weeks after any change; blood pressure and HbA1c at each visit; review ticagrelor duration at 12 months [6].

Probing questions with model answers

"He tells you statins destroyed his workmate's muscles. How do you respond?" — "I would not dismiss it. Severe statin myopathy exists but is rare — rhabdomyolysis occurs in about one to three per hundred thousand patient-years — while mild aches are common and usually not caused by the tablet. I would offer him a structured trial: stop, confirm the ache settles, restart at a lower dose, and compare — his own data, not my opinion. SAMSON did exactly this formally and found placebo reproduced about 90% of the symptom burden" [2].

"What if his CK comes back at 3,000 with dark urine?" — "That changes everything: stop the statin and do not rechallenge with the same agent soon, check creatinine, potassium and urinalysis, hydrate, and manage as rhabdomyolysis. His future LDL lowering would be built on ezetimibe and bempedoic acid, with a PCSK9 antibody if events continue — and I would document the reaction formally" [4] [7].

"Why do you care about the rehabilitation so much — is it not just exercise classes?" — "Because the Cochrane meta-analysis of 63 trials and nearly 15,000 patients shows exercise-based rehabilitation cuts cardiovascular death by about a quarter — a drug-sized effect — plus fewer readmissions and better quality of life. A referral I do not chase is a prescription I did not fill, so I will problem-solve attendance with him directly" [5].

"His LDL on 80 mg atorvastatin was 1.9 mmol/L. Is that good enough?" — "No — for very-high-risk secondary prevention I target below 1.4 mmol/L and at least a 50% fall from baseline, because the CTT analyses show a log-linear relationship: each further 1.0 mmol/L fall buys about a fifth fewer major vascular events, with no floor seen in the trials" [6].

"When do you stop his ticagrelor?" — "After 12 months of dual therapy for an NSTEMI with a stent, unless bleeding forces earlier review or ischaemic features argue for extension — a decision I make at the 12-month mark with his bleeding risk on the table, not by default" [1].

Communication points

• Validate before you educate: his symptom experience is real even when the attribution is wrong — say so before quoting nocebo data [2].
• Use absolute numbers for his decisions: his risk, his benefit from the statin, his gain from quitting smoking [1].
• Document the statin discussion and the rechallenge plan clearly so the next prescriber does not inherit a label of "statin allergy" that never happened [2].